DANVERS, Mass. – October 28, 2024 – Results were presented at Transcatheter Cardiovascular Therapeutics (TCT) 2024 conference from the first completed pivotal trial on patients supported with Impella ...

Abiomed, part of Johnson & Johnson MedTech, recently presented positive results from the first completed pivotal trial on Impella ECP, a novel transvalvular axial flow pump with compressible pump ...

DANVERS, Mass.--(BUSINESS WIRE)--The United States Food and Drug Administration (FDA) has granted breakthrough device designation to Abiomed’s (NASDAQ: ABMD) Impella ECP expandable percutaneous heart ...

Results were presented at Transcatheter Cardiovascular Therapeutics, or TCT, 2024 conference from the first completed pivotal trial on patients supported with Impella ECP, a novel transvalvular axial ...

Abiomed, Inc. ABMD announced receipt of the FDA’s breakthrough device designation for its Impella ECP expandable percutaneous heart pump. Bestowing of the designation implies that the FDA will ...

Danvers, Mass.-based medical device company Abiomed received the FDA’s breakthrough device designation for its Impella ECP heart pump. The designation means the FDA will prioritize the device’s ...

Abiomed Inc. is one of a number of companies whose share prices took a hit in the early days of the COVID-19 pandemic, but the company has since rebounded, thanks in part to the news that the FDA has ...

Abiomed Inc. is one of a number of companies whose share prices took a hit in the early days of the COVID-19 pandemic, but the company has since rebounded, thanks in part to the news that the FDA has ...

DANVERS, Mass.--(BUSINESS WIRE)--Abiomed (NASDAQ: ABMD) announces the first two patients have been treated with the Impella ECP expandable percutaneous heart pump. Impella ECP is the smallest heart ...

Impella ECP is a technology of Abiomed, part of Johnson & Johnson MedTech, and the global leader in heart recovery. The pivotal investigational device exemption (IDE) study, which enrolled 256 ...